Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study
Description Effect of MD1003 in Progressive Multiple Sclerosis

Randomized double blind placebo-controlled for at least 15 months, followed by an open label extension phase of up to 12 months.

Study visits will be in downtown Buffalo
Objective The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.
Principal Investigator WEINSTOCK-GUTTMAN, BIANCA
Age Group Adult
Drugs Involved
Status Open
Key Eligibility Ages 18-65
Multiple Sclerosis (MS)
Disease Group Brain/Neurological Disorders
Treatment MD1003